Literature DB >> 1620962

Comparison of the pathogenicity for pregnant sheep of Rift Valley fever virus and a live attenuated vaccine.

A Baskerville1, K A Hubbard, J R Stephenson.   

Abstract

A live attenuated mutant of Rift Valley fever virus, MV P12, was previously shown to be non-pathogenic in young lambs, but capable of producing protective immunity. The studies reported here show that the abortion in sheep caused by an infection with virulent virus is the result of necrosis of the maternal villi and cotyledons arising from an acute inflammation of the maternal caruncles. Pregnant ewes infected with the attenuated mutant virus MV P12 showed none of these lesions in the placenta and gave birth to healthy lambs. Colostrum from ewes infected with MV P12 virus was able to induce protective immunity in the offspring. These data along with previously published results suggest that the mutant virus MV P12 is an excellent candidate for use as a live attenuated veterinary vaccine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1620962     DOI: 10.1016/0034-5288(92)90029-2

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  12 in total

1.  Evaluation of the Efficacy, Potential for Vector Transmission, and Duration of Immunity of MP-12, an Attenuated Rift Valley Fever Virus Vaccine Candidate, in Sheep.

Authors:  Myrna M Miller; Kristine E Bennett; Barbara S Drolet; Robbin Lindsay; James O Mecham; Will K Reeves; Hana M Weingartl; William C Wilson
Journal:  Clin Vaccine Immunol       Date:  2015-06-03

Review 2.  Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.

Authors:  Tetsuro Ikegami
Journal:  Expert Rev Vaccines       Date:  2017-05-02       Impact factor: 5.217

Review 3.  Rift valley fever vaccines.

Authors:  Tetsuro Ikegami; Shinji Makino
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

4.  Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates.

Authors:  Phillip R Pittman; Sarah L Norris; Elizabeth S Brown; Manmohan V Ranadive; Barbara A Schibly; George E Bettinger; Nandadeva Lokugamage; Lawrence Korman; John C Morrill; Clarence J Peters
Journal:  Vaccine       Date:  2015-12-17       Impact factor: 3.641

5.  Chemotactic and inflammatory responses in the liver and brain are associated with pathogenesis of Rift Valley fever virus infection in the mouse.

Authors:  Kimberly K Gray; Melissa N Worthy; Terry L Juelich; Stacy L Agar; Allison Poussard; Dan Ragland; Alexander N Freiberg; Michael R Holbrook
Journal:  PLoS Negl Trop Dis       Date:  2012-02-28

6.  Development of a novel, single-cycle replicable rift valley Fever vaccine.

Authors:  Shin Murakami; Kaori Terasaki; Sydney I Ramirez; John C Morrill; Shinji Makino
Journal:  PLoS Negl Trop Dis       Date:  2014-03-20

7.  Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination.

Authors:  Gema Lorenzo; Elena López-Gil; Javier Ortego; Alejandro Brun
Journal:  Vet Res       Date:  2018-02-21       Impact factor: 3.683

Review 8.  Current Status of Rift Valley Fever Vaccine Development.

Authors:  Bonto Faburay; Angelle Desiree LaBeaud; D Scott McVey; William C Wilson; Juergen A Richt
Journal:  Vaccines (Basel)       Date:  2017-09-19

9.  Rift Valley Fever Vaccine Virus Clone 13 Is Able to Cross the Ovine Placental Barrier Associated with Foetal Infections, Malformations, and Stillbirths.

Authors:  Birgit Makoschey; Emma van Kilsdonk; Willem R Hubers; Mieke P Vrijenhoek; Marianne Smit; Paul J Wichgers Schreur; Jeroen Kortekaas; Véronique Moulin
Journal:  PLoS Negl Trop Dis       Date:  2016-03-31

Review 10.  Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile.

Authors:  Thomas P Monath; Jeroen Kortekaas; Douglas M Watts; Rebecca C Christofferson; Angelle Desiree LaBeaud; Brian Gowen; Clarence J Peters; Darci R Smith; Robert Swanepoel; John C Morrill; Thomas G Ksiazek; Phillip R Pittman; Brian H Bird; George Bettinger
Journal:  Vaccine X       Date:  2020-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.